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Soluble guanylate cyclase
Nitric oxideSoluble Guanylate Cyclase (sGC) is the receptor for the signalling agent nitric oxide (NO) and catalyses the
production of the second messenger cyclic guanosine monophosphate (cGMP) from guanosine triphos-
phate (GTP). The enzyme is an attractive drug target for small molecules that act in the cardiovascular
and pulmonary systems, and has also shown to be a potential target in neurological disorders. We have
discovered that 5-(indazol-3-yl)-1,2,4-oxadiazoles activate the enzyme in the absence of added NO and
shown they bind to the catalytic domain of the enzyme after development of a surface plasmon reso-
nance assay that allows the biophysical detection of intrinsic binding of ligands to the full length sGC
and to a construct of the catalytic domain.
 2014 The Authors. Published by Elsevier Ltd. All rights reserved.Soluble guanylate cyclase (guanylyl cyclase; sGC; EC 4.6.1.2) is a
heterodimeric enzyme endogenously activated by the binding of
nitric oxide (NO) to a prosthetic haem group, leading to a confor-
mational change that increases the rate of GTP conversion into
cGMP. The second messenger cGMP is a substrate of phosphodies-
terases (PDEs), ligand-gated ion channels, and cGMP-dependent
protein kinases, resulting in a number of downstream outputs.
The NO/sGC/cGMP signalling has an important role in regulating
blood ﬂow, and in the perfusion and function of many organs
and tissues. Increased levels of cGMP lead to smooth muscle relax-
ation, inhibition of platelet aggregation and anti-inﬂammatory effects.
Reduced levels or responsiveness to NO contributes to the
development of cardiovascular, pulmonary and hepatic diseases.
In contrast, aberrant signalling has also been linked to vascular dis-
orders such as hypertension, atherosclerosis and coronary heart
diseases and has also been shown to occur during sepsis and neu-
rodegenerative disorders.1,2 From a drug design perspective, sGC is
an attractive target for small molecule modulators and activators
are currently under clinical development for the treatment of car-
diovascular diseases.3,4 sGC is generally found as a heterodimer
composed of a b-subunit (70 kDa) and a larger a-subunit
(82 kDa). The best characterized isoform is the a1/b1 protein, buta2/b1 is also abundant in the brain.5 Each subunit is composed of
multiple domains: The haem-nitric oxide binding domain of sGC
is located at the N-terminus and Histidine-105 in the b-subunit
is the proximal haem ligand; PAS-like domains are present in both
subunits and are thought to direct preferential heterodimer forma-
tion; turnover of GTP into cGMP occurs at the C-terminus catalytic
domain of the enzyme. Whilst the crystal structure of the full
length sGC remains unknown, structures of the catalytic domain
heterodimer and b-homodimer have been determined (PDB entries
3UVJ and 2WZI, respectively).6 The catalytic domain of human sGC
possesses two well-deﬁned binding sites, one site responsible for
catalysis and one allosteric binding site (also referred to as the
pseudosymmetric site), which is thought to be able to accommo-
date small molecules that control enzyme activity in a manner
similar to forskolin in the binding pocket of adenylyl cyclase.6,7 It
has also been proposed that ATP binds to both sites in sGC and
inhibits sGC activity via competition with GTP, highlighting the po-
tential for allosteric regulation of the enzyme.2,8,9
There are currently two compound classes known to activate
sGC by different mechanisms, one that acts in the absence of NO
by replacing the haem moiety, such as BAY 58-2667 (cinaciguat,
1) and a second class of compounds such as the benzylindazole
derivative YC-1 (2) which is thought to bind to an allosteric site
and act synergistically with NO to increase cGMP production.10
Activators derived from YC-1 include the well-characterisedpyraz-
olopyridine BAY 41-2272 (3) (Fig. 1) which acts in a similar fashion.
The mechanisms by which synthetic small molecules activate
enzymes differ in many ways from those that apply to inhibitors
Figure 1. Chemical structure of sGC activators.
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understand their mode of action. Activators commonly bind to an
allosteric binding site and require lower doses than inhibitors to
cause an effect.11 Current biochemical characterisation of sGC
modulation by small molecules is performed by measuring cGMP
levels with radioimmunoassays. Biophysical characterisation of the
enzyme can also be performed using spectroscopy such as Raman
and electron paramagnetic resonance.12,13 We considered that a
biophysical method, surface plasmon resonance, would allow the
detection of direct binding of small molecules to sGC and would
complement the biochemical characterisation of compounds.
Surface Plasmon Resonance (SPR) is now recognised as a valu-
able tool to screen and characterise small molecules that modulate
the activity of a range of targets, including kinases and G protein-
coupled receptors (GPCRs).14–16 The microﬂuidics system of the
biosensor allows the injection of the compound over an immobi-
lised protein and the optical detector measures the direct binding
between the two entities based on the difference in refractive index
near the surface that occurs as the compound binds, thus allowing a
real-time and label-free measurement of compound binding to the
target. The technique allows the determination of kinetic and ther-
modynamic parameters. Added beneﬁts of using SPR-based assays
include the ability to screen fragments (fragment-based drug de-
sign) and the use of separate domains of the protein, which may
provide information about the location of the binding site. Further
studies with mutated constructs may also allow additional charac-
terisation of the binding mode when crystal structures are not
available. We have developed a new assay that measures direct
binding of compounds to the sGC enzyme using SPR. The SPR assay
was developed to provide a fast means of assaying intrinsic binding
of compounds to both the full length human recombinant enzyme
and a construct of the catalytic domain only (sGCcat).
The ﬁrst lead sGC activator was YC-1 (2), an indazole derivative
that increases cGMP concentration in the presence of NO. YC-1 (2)
is also capable of inhibiting sodium channels in a voltage-depen-
dent manner, and it was used as the starting point for the design
of a library of sodium channel modulators.17–19 In this Letter we re-
port cross-screening of this library against sGC and the discovery of
new activators of the enzyme.
A subset of 10 drug-like compounds was selected for evaluation
(Table 1). Design, synthesis, and full characterisation of these com-
pounds has been reported elsewhere.19 The core structure of these
compounds is made of an indazole substituted in the 3-position
with a 1,2,4-oxadiazole. The main variations in the selected com-
pounds were the substituent groups in the N1 and N2 positions of
the indazole (R1) and the groups in the 3-position of the oxadiazole,
which included tert-butyl carbamate and free-amine groups (R2).
The large heterodimeric structure of sGC makes it particularly
challenging to detect binding of low molecular weight compounds
using SPR. Whilst higher concentrations of protein on the sensorchip provide a higher signal to noise ratio, a denser surface is also
prone to higher non-speciﬁc binding and hindrance of the binding
site. We evaluated if a construct of the a1b1 catalytic domain of
sGC could be used as a model for the detection of binding to sGC.
The catalytic domain of sGC (sGCcat) is easier to manipulate in
an SPR assay—its smaller size (50 kDa) allows the use of a less
dense surface (lower immobilisation level), which reduces steric
effects and non-speciﬁc electrostatic binding whilst still providing
a high enough signal/noise ratio.
Both protein constructs, full length and catalytic domain only,
were immobilised via amine coupling to a CM5 sensor chip of a
Biacore T200 instrument in the presence of ATP and GTP to protect
the binding sites.20 Expression and puriﬁcation of the catalytic do-
main of sGC was performed as previously described except that the
protein was ﬁnally buffer exchanged in to 50 mM HEPES, pH 7.5,
300 mM NaCl, 5% glycerol, in order to make it ameanable to
amine-coupling.6 A biochemical assay for sGC activation was also
employed. Activation of human recombinant sGC took place in
the presence of GTP and the cofactor Mg2+, without any added
NO.21 Enzyme activity was determined by measuring cGMP pro-
duction using a standard cGMP [3H] radioimmunoassay system.22
Binding of both nucleotide triphosphates (NTPs) to the immobi-
lised proteins in the SPR assay was observed at physiological con-
centrations in the presence of Mg2+, which was present at 10 mM
in the running buffer, whilst binding of cGMP only shifted from
the baseline at concentrations higher than 1 mM. Surface satura-
tion could not be observed, as NTPs are known to aggregate at con-
centrations higher than 1 mM23 (Fig. 2). However, binding curves
were ﬁt to a nonlinear curve model that considers binding plus lin-
ear non-speciﬁc binding. The ﬁt was consistent with GTP binding
to one binding site (n = 1) and ATP binding more than one site
(n = 1.2) (Fig. 3). The conformation of the catalytic domain of sGC
is thought to change signiﬁcantly upon activation and ‘open’ and
‘closed’ states have been suggested.6 Although it is not possible
to know in which conformation the protein was immobilised, bind-
ing of ATP and GTP shows that binding sites are accessible.
Both proteins tolerated DMSO concentrations of up to 5% which
allowed binding of the small molecules to be evaluated using this
system. The binding level of all compounds was measured at
100 lM.24,25
With realistic responses observed for the nucleotides GTP,
cGMP and ATP we next tested known activators in the SPR assay.
Binding to the full-length enzyme was non-stoichiometric, indicat-
ing there is more than one site where small molecules can bind
non-speciﬁcally. Nonetheless, YC-1 (2) demonstrated strong bind-
ing to both proteins indicating its binding site can be located in the
catalytic domain, consistent with previous investigations.26 In con-
trast, the heme mimetic BAY 58-2667 (1), which is known to bind
to the heme domain, showed strong binding to the full length sGC
and only non-speciﬁc binding to sGCcat, as per analysis of the sen-
sorgrams (see Supplementary information).
Competition between ATP and GTP at 1 mM each was observed,
as the biosensor response for binding of both nucleotides together
was lower than the sum of their separate binding responses. Con-
versely, GTP and YC-1 (2) showed additive binding, suggesting
binding of the small molecule to the pseudosymmetric site of the
catalytic domain (Table 1).
We next evaluated the indazoleoxadiazole compound library in
the SPR and biochemical assays (Table 2). The binding response of
the compounds to sGCcat were converted into percent occupancy,
deﬁned as the possible number of immobilised sites occupied by
the compoundat equilibrium, assuminga stoichiometric interaction
between the compound and the enzyme. Compounds with highest
afﬁnity would also show higher percent occupancy (Table 1).27
Compounds 4 and 5 are close analogues, differing only in the
position of a methyl group, and both give a high binding response
Table 1
Structures of selected compounds tested for sGC activity
N
N
O
NN
HN
R2
N
N R2
O
N
N
HN
R1 R1
Compound R1 R2 cGMP production (pmol/ng protein) Percent occupancy of sGCcat
2 — — 22.70 ± 3.15 85
4 H
N1
14.35 ± 0.11 90
5 H
N1
3.22 ± 0.15 101
6 H
N1
O
2.33 ± 0.15 21
7 H
N1
O
N 9.09 ± 0.31 34
8 H
N1
O
4.05 ± 0.33 20
9
O
O
N1
N
H
O 2.23 ± 0.06 62
10
O
O
N1
O
O 15.56 ± 1.3 40
11 H
N2
Cl
2.08 ± 0.01 94
12 H
N2
O
O 9.11 ± 0.07 96
13 H
N2
N N
2.72 ± 0.22 28
DMSO control 2.21 ± 0.15
Figure 2. Sensorgrams for ATP (A), GTP (B), and cGMP (C) binding to sGCcat. The binding of the nucleotides at concentrations 0.13–3 mM was monitored for 30 s in the
presence of the cofactor Mg2+ (n = 2).
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zyl-substituted indazole 5 does not activate the enzyme in the bio-
chemical assay. Replacement of the methyl group in the 4-position
of compound 4 by a methoxy group in compound 6 not onlyrenders the compound inactive but also prevents it from binding
to the enzyme in the SPR assay.
Further variations at the N1 substituted indazole include a 5-
methylisoxazole in compound 7 and an ethanone in compound 8.
Figure 3. Fitting curves for ATP and GTP binding to sGCcat.(A) ATP binds to the
receptor with a stoichiometry of 1.2 and KD = 848.87 lM.(B) GTP binds sGCcat with
a stoichiometry of 1 and KD = 326.41 lM. (n = 2).
Table 2
Binding of ATP and YC-1 (2) in the presence of GTP
Compound Biosensor response
(RU)
Additive
response
ATP (1 mM) 23.04 ± 0.46
GTP (1 mM) 10.67 ± 0.61
YC-1 (2) (100 lM) 7.10 ± 0.66
GTP (2 mM) + ATP (2 mM) 25.95 ± 1.00 33.71
GTP (2 mM) + YC-1(2) (100 lM) 18.42 ± 1.04 17.77
1078 F. Mota et al. / Bioorg. Med. Chem. Lett. 24 (2014) 1075–1079The latter showed low binding to sGC and no activity in the bio-
chemical assay. Compound 7 on the other hand, activated the en-
zyme and also showed binding in the SPR assay to a lower extent
than compound 4.
The tert-butyl carbamate substituted (1,2,4-oxadiazol-3-
yl)methanamines 9 and 10 vary in the substituents at the N1 of
the indazole core. The 5-ethylbenzo[d][1,3]dioxole compound 10
is capable of activating sGC and shows signiﬁcant binding to the
enzyme, whilst the N-(4-ethylphenyl)acetamide compound 9, de-
spite showing higher binding than 10 is inactive in the biochemical
assay. The acetamide group, which is both a hydrogen bond donor
and acceptor, might contribute to a higher binding afﬁnity, but this
is not necessarily required for activity.
Three compounds (11–13) were selected in which the indazole
core was substituted at the N2 position, and whilst compounds
11 and 12 showed binding to sGC they did not exhibit any biological
activity. Unfortunately the pyrazolopyridine derivative BAY 41-
2272 (3) showed poor solubility in the assay buffers even with 5%
DMSO and crystallised in the assay plates preventing evaluation.
The binding of the indazoleoxadiazole compounds to the full-
length sGC correlates with the binding to the catalytic domain con-
struct, providing evidence that the binding site for this class of
compounds is at the catalytic domain of sGC. This is most likely
at the pseudosymmetric site, as previously suggested by structural
models of YC-1 (2) interaction with the catalytic core of sGC and
additive binding of the compound with GTP.26 No correlation
was observed between binding level and lipophilicity (C logP) of
the compounds (shown in Supplementary information). Notably
no binding was found for BAY 58-2667 (1) to the catalytic domain.
The SPR assay detects binding alone and is not expected to corre-
late with biochemical activation and, based on our data, does not
do so. However, binding must be a pre-requisite for activity and
we did not observe biochemical activation without binding.
In summary, we have described a new assay that detects intrin-
sic binding of nucleotides and small molecules to the NO-receptor
sGC, and provided further evidence that the so-called NO-indepen-
dent sGC activators act through binding to an allosteric site on the
catalytic domain of the enzyme. We utilised the assay to evaluate a
library of YC-1 (2) related compounds and discovered some newindazoleoxadiazole activators as a result. The a1b1 sGC catalytic
domain construct used in this assay can therefore be used as a
model for sGC binding in further SPR-based studies, providing a
simple direct method to enable fragment-based drug design and
inhibitor screening.
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